Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed stage IV melanoma~  * Multiple primary melanomas allowed~ * Metastasis may be from a cutaneous, mucosal, ocular, or unknown primary site~* Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST criteria)~* Must have 2 extremities uninvolved with tumor~* Must have at least 2 intact (undissected) axillary and/or inguinal lymph node basins~  * Prior sentinel node biopsy may not have violated the integrity of a nodal basin~    * This extremity may still be considered for vaccination~* Human Lymphocyte Antigen (HLA)-A1, -A2, or -A3 positive~* Prior brain metastases allowed provided all of the following are true:~  * Surgically resected or treated with gamma-knife or stereotactic radiosurgery~ * No disease progression in the brain for the past 3 months~ * More than 30 days since prior steroids for the management of brain metastases~* Age: 18 and over~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Adequate organ function measured within 4 weeks before randomization:~  * White blood cell (WBC) at least 4,000/mm\^3~ * Platelet count at least 100,000/mm\^3~ * Lymphocyte count at least 700/mm\^3~ * Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) no greater than 2 times upper limit of normal (ULN)~ * Bilirubin no greater than 2 times ULN~ * Alkaline phosphatase no greater than 2 times ULN~ * Lactic dehydrogenase no greater than 2 times ULN~ * Creatinine no greater than 1.8 mg/dL~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except nonmetastatic squamous cell or basal cell skin cancer, ductal or lobular carcinoma in situ of the breast, or carcinoma in situ of the cervix~* At least 4 weeks since prior sargramostim (GM-CSF), interferon alfa-2b, or interleukin-2~* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)~* More than 30 days since prior systemic corticosteroids, including any of the following:~  * Therapeutic doses of oral steroids (e.g., prednisone or dexamethasone)~ * Steroid inhalers (e.g., Advair)~    * Topical steroids and nasal steroids with low systemic absorption (e.g., fluticasone) or steroids with low systemic absorption (e.g., triamcinolone hexacetonide) injected into a joint space allowed~* At least 4 weeks since prior local control or palliative radiotherapy and recovered~* Recovered from prior major surgery~Exclusion criteria:~* More than 3 brain metastases~* Metastatic lesions greater than 2 cm~* Concurrent radiotherapy~* Prior radiotherapy to measurable disease~* Concurrent surgery~* Concurrent corticosteroids~* Concurrent topical or systemic steroids~* Concurrent chemotherapy~* Prior vaccination with any of the study peptides~* Recent (within the past year) or concurrent addiction to alcohol or illicit drugs~* Pregnant or nursing~* Known or suspected major allergy to any components of the study vaccine~* Significant detectable infection~* Immunosuppression conditions~* Prior or active autoimmune disorder requiring cytotoxic or mmunosuppressive therapy, except for any of the following:~  * Presence of laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody (ANA) titer) without symptoms~ * Clinical evidence of vitiligo or other forms of depigmenting illness~ * Mild arthritis requiring nonsteroidal anti-inflammatory medication~* Autoimmune disorder with visceral involvement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (12MP) (Type: EXPERIMENTAL): Patients receive 2 injections of multi-epitope peptide vaccine comprising 12 melanoma peptides restricted by Class I MHC (12MP) emulsified with sargramostim (GM-CSF) and Montanide ISA-51 (incomplete Freund's adjuvant) or Montanide ISA-51 VG (ISA-51) intradermally (ID) and subcutaneously (SC) on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
- Arm II (12MP/Tet) (Type: EXPERIMENTAL): Patients receive 2 injections of multi-epitope peptide vaccine comprising multi-epitope melanoma peptide vaccine (12MP) and 1 tetanus peptide melanoma vaccine emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
- Arm III (12MP/6MHP) (Type: EXPERIMENTAL): Patients receive 2 injections of multi-epitope peptide vaccine comprising multi-epitope melanoma peptide vaccine (12MP) and 6 melanoma helper peptides (6HP) emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
- Arm IV (6MHP) (Type: EXPERIMENTAL): Patients receive 2 injections of multi-epitope peptide vaccine comprising melanoma helper peptide vaccine (6HP) emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete